X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dichlorphenamide
Therapeutic Area: Rare Diseases and Disorders Product Name: Keveyis
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Xeris Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 24, 2021
Details:
The acquisition diversifies revenue base with two rapidly growing brands in Xeris’ Gvoke® and Strongbridge’s KEVEYIS®.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Canakinumab
Therapeutic Area: Rare Diseases and Disorders Product Name: Ilaris
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
This new indication follows the existing approval of Ilaris for Systemic Juvenile Idiopathic Arthritis (SJIA)1, now allowing patients over the age of 16 to be treated. Ilaris is an interleukin-1 beta inhibitor that provides a new mode of treatment for this disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anakinra
Therapeutic Area: Rare Diseases and Disorders Product Name: Kineret
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
Details:
NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis (sJIA) in people aged eight months or over with a body weight of 10kg or more, who have not responded to at least one conventional disease modifying antirheumatic drug (DMARD).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
